CA3020275C - Agents de degradation de proteine mdm2 - Google Patents

Agents de degradation de proteine mdm2

Info

Publication number
CA3020275C
CA3020275C CA3020275A CA3020275A CA3020275C CA 3020275 C CA3020275 C CA 3020275C CA 3020275 A CA3020275 A CA 3020275A CA 3020275 A CA3020275 A CA 3020275A CA 3020275 C CA3020275 C CA 3020275C
Authority
CA
Canada
Prior art keywords
another embodiment
group
disclosure
compounds
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3020275A
Other languages
English (en)
Other versions
CA3020275A1 (fr
Inventor
Shaomeng Wang
Yangbing Li
Jiuling Yang
Angelo Aguilar
Bing Zhou
Jiantao Hu
Fuming Xu
Rohan Rej
Xin Han
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Priority claimed from PCT/US2017/026274 external-priority patent/WO2017176957A1/fr
Publication of CA3020275A1 publication Critical patent/CA3020275A1/fr
Application granted granted Critical
Publication of CA3020275C publication Critical patent/CA3020275C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente divulgation concerne les composés représentés par la formule I-A : A1-L1-B1 I-A et les sels, hydrates et solvates pharmaceutiquement acceptables de ceux-ci, dans lesquels A1, B1 et L1 sont tels que définis dans la spécification. Elle concerne également des composés de la formule I-A qui peuvent être utilisés pour traiter une condition ou un trouble sensible à la dégradation de la protéine MDM2, comme le cancer. Ces composés comprennent les composés de la formule suivante : (voir la formule ci-dessus)
CA3020275A 2016-04-06 2017-04-06 Agents de degradation de proteine mdm2 Active CA3020275C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662318974P 2016-04-06 2016-04-06
US62/318,974 2016-04-06
US201662393874P 2016-09-13 2016-09-13
US62/393,874 2016-09-13
US201662409571P 2016-10-18 2016-10-18
US62/409,571 2016-10-18
PCT/US2017/026274 WO2017176957A1 (fr) 2016-04-06 2017-04-06 Agents de dégradation de protéine mdm2

Publications (2)

Publication Number Publication Date
CA3020275A1 CA3020275A1 (fr) 2017-10-12
CA3020275C true CA3020275C (fr) 2026-01-20

Family

ID=

Similar Documents

Publication Publication Date Title
EP3440066B1 (fr) Agents de dégradation de protéine mdm2
US20210198237A1 (en) Piperidines as menin inhibitors
EP3628044B1 (fr) Pyrrolo[2,3]pyridines et leurs analogues associés en tant qu' inhibiteurs de lsd-1
US11045448B2 (en) Piperidines as covalent menin inhibitors
US20210115018A1 (en) Piperidine compounds as covalent menin inhibitors
WO2022187419A1 (fr) Agents de dégradation à petites molécules du récepteur des androgènes
WO2022011205A1 (fr) Agents de dégradation de protéine de récepteur des androgènes
WO2020072391A1 (fr) Inhibiteurs de ménine à petites molécules
CA3020275C (fr) Agents de degradation de proteine mdm2
BR112018070549B1 (pt) Degradantes de proteína mdm2, composição farmacêutica e seus usos
WO2025137613A1 (fr) Agents de dégradation de la protéine nrf2 à base de cycloalkylènes
HK40041770B (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40026020B (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
HK40026020A (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
HK40006016A (en) Piperidines as menin inhibitors
HK40006016B (en) Piperidines as menin inhibitors